FOXK1 promotes hormonally responsive breast carcinogenesis by suppressing apoptosis

Abstract

Background: Globally, breast cancer constitutes the predominant malignancy in women. Abnormal regulation of epigenetic factors plays a key role in the development of tumors. Anti-apoptosis is a characteristic of tumor cells. Therefore, exploring and identifying relevant epigenetic factors that regulate the apoptosis of tumor cells is the foundation for clarifying the pathogenesis of tumors and achieving precision antitumor therapy.

Method: This study focused on exploring the epigenetic mechanism of FOXK1 in the development of estrogen receptor-positive (ER⁺) breast cancer. We used overexpressing FLAG-FOXK1 MCF-7 cells to perform silver staining mass spectrometry analysis and conducted Co-IP experiments to verify the interactions. ChIP-seq was conducted on MCF-7 cells to examine FOXK1's binding across the genome and its transcriptional target sites. To validate the ChIP-seq results, qChIP, western blotting, and quantitative polymerase chain reaction (qPCR) were performed. Through TUNEL assay, cell counting assay, colony formation assay, and the mouse xenograft models, the effect of FOXK1 on breast cancer progression was detected. Finally, by analyzing online databases, the correlation between FOXK1 and the survival of breast cancer patients was examined.

Results: FOXK1 interacts with the REST/CoREST transcriptional corepression complex to transcriptionally inhibit target genes representing the apoptotic pathway. Abnormally high expression of FOXK1 prevents the apoptosis of ER⁺ breast cancer cells in vitro and promotes ER⁺ breast tumor progression in vivo. Furthermore, the expression of FOXK1 is negatively correlated with the survival of ER⁺ breast cancer patients.

Conclusion: FOXK1 promotes ER⁺ breast carcinogenesis through anti-apoptosis and acts as a potential target for ER⁺ breast cancer treatment.

Keywords

apoptosis / estrogen receptor-positive breast cancer / FOXK1 / transcription repression

References

[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72: 7-33.

[2] Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet. 2005; 365: 1727-1741.

[3] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209-249.

[4] Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond). 2019; 39: 22.

[5] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66: 115-132.

[6] Sajjad H, Imtiaz S, Noor T, Siddiqui YH, Sajjad A, Zia M. Cancer models in preclinical research: a chronicle review of advancement in effective cancer research. Animal Model Exp Med. 2021; 4: 87-103.

[7] Aouad P, Zhang Y, De Martino F, et al. Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence. Nat Commun. 2022; 13: 4975.

[8] Sun L, Zhang H, Gao P. Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell. 2022; 13: 877-919.

[9] Liu X, Xin Z, Wang K. Patient-derived xenograft model in colorectal cancer basic and translational research. Animal Model Exp Med. 2023; 6: 26-40.

[10] Wang Y, Li Z, Zhang Z, Chen X. Identification ACTA2 and KDR as key proteins for prognosis of PD-1/PD-L1 blockade therapy in melanoma. Animal Model Exp Med. 2021; 4: 138-150.

[11] Zhou X, Sun Z, Zhang M, et al. Deficient Rnf43 potentiates hyperactive Kras-mediated pancreatic preneoplasia initiation and malignant transformation. Animal Model Exp Med. 2022; 5: 61-71.

[12] Golson ML, Kaestner KH. Fox transcription factors: from development to disease. Development. 2016; 143: 4558-4570.

[13] Liu Y, Ding W, Ge H, et al. FOXK transcription factors: regulation and critical role in cancer. Cancer Lett. 2019; 458: 1-12.

[14] Kaestner KH, Knochel W, Martinez DE. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev. 2000; 14: 142-146.

[15] Zaret K. Developmental competence of the gut endoderm: genetic potentiation by GATA and HNF3/fork head proteins. Dev Biol. 1999; 209: 1-10.

[16] Herman L, Todeschini AL, Veitia RA. Forkhead transcription factors in health and disease. Trends Genet. 2021; 37: 460-475.

[17] Bowman CJ, Ayer DE, Dynlacht BD. Foxk proteins repress the initiation of starvation-induced atrophy and autophagy programs. Nat Cell Biol. 2014; 16: 1202-1214.

[18] Wang W, Li X, Lee M, et al. FOXKs promote Wnt/β-catenin signaling by translocating DVL into the nucleus. Dev Cell. 2015; 32: 707-718.

[19] Sukonina V, Ma H, Zhang W, et al. FOXK1 and FOXK2 regulate aerobic glycolysis. Nature. 2019; 566: 279-283.

[20] He L, Gomes AP, Wang X, et al. mTORC1 promotes metabolic reprogramming by the suppression of GSK3-dependent Foxk1 phosphorylation. Mol Cell. 2018; 70: 949-960.e4.

[21] Shi X, Wallis AM, Gerard RD, et al. Foxk1 promotes cell proliferation and represses myogenic differentiation by regulating Foxo4 and Mef2. J Cell Sci. 2012; 125: 5329-5337.

[22] Meeson AP, Shi X, Alexander MS, et al. Sox15 and Fhl3 transcriptionally coactivate Foxk1 and regulate myogenic progenitor cells. EMBO J. 2007; 26: 1902-1912.

[23] Shan L, Zhou X, Liu X, et al. FOXK2 elicits massive transcription repression and suppresses the hypoxic response and breast cancer carcinogenesis. Cancer Cell. 2016; 30: 708-722.

[24] Zheng S, Yang L, Zou Y, et al. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer. J Hematol Oncol. 2020; 13: 17.

[25] Gao F, Tian J. FOXK1, regulated by miR-365-3p, promotes cell growth and EMT indicates unfavorable prognosis in breast cancer. Onco Targets Ther. 2020; 13: 623-634.

[26] Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science. 1995; 267: 1360-1363.

[27] Chong JA, Tapia-Ramirez J, Kim S, et al. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell. 1995; 80: 949-957.

[28] Andrés ME, Burger C, Peral-Rubio MJ, et al. CoREST: a functional corepressor required for regulation of neural-specific gene expression. Proc Natl Acad Sci U S A. 1999; 96: 9873-9878.

[29] Ouyang J, Shi Y, Valin A, Xuan Y, Gill G. Direct binding of CoREST1 to SUMO-2/3 contributes to gene-specific repression by the LSD1/CoREST1/HDAC complex. Mol Cell. 2009; 34: 145-154.

[30] Qureshi IA, Gokhan S, Mehler MF. REST and CoREST are transcriptional and epigenetic regulators of seminal neural fate decisions. Cell Cycle. 2010; 9: 4477-4486.

[31] Mulligan P, Westbrook TF, Ottinger M, et al. CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. Mol Cell. 2008; 32: 718-726.

[32] Guardavaccaro D, Frescas D, Dorrello NV, et al. Control of chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature. 2008; 452: 365-369.

[33] Coulson JM. Transcriptional regulation: cancer, neurons and the REST. Curr Biol. 2005; 15: R665-R668.

[34] Yang Y, Huang W, Qiu R, et al. LSD1 coordinates with the SIN3A/HDAC complex and maintains sensitivity to chemotherapy in breast cancer. J Mol Cell Biol. 2018; 10: 285-301.

[35] Liu J, Feng J, Li L, et al. Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer. EMBO Rep. 2020; 21: e48597.

[36] Byun JS, Park S, Yi DI, et al. Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein. Cell Death Dis. 2019; 10: 689.

[37] Qin Y, Vasilatos SN, Chen L, et al. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene. 2019; 38: 390-405.

[38] Kalin JH, Wu M, Gomez AV, et al. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018; 9: 53.

[39] Croce CM, Reed JC. Finally, an apoptosis-targeting therapeutic for cancer. Cancer Res. 2016; 76: 5914-5920.

[40] Chang L, Graham PH, Hao J, et al. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis. 2014; 5: e1437.

[41] Concannon CG, Tuffy LP, Weisová P, et al. AMP kinase-mediated activation of the BH3-only protein Bim couples energy depletion to stress-induced apoptosis. J Cell Biol. 2010; 189: 83-94.

[42] Kilbride SM, Farrelly AM, Bonner C, et al. AMP-activated protein kinase mediates apoptosis in response to bioenergetic stress through activation of the pro-apoptotic Bcl-2 homology domain-3-only protein BMF. J Biol Chem. 2010; 285: 36199-36206.

[43] Tanaka K, Yu HA, Yang S, et al. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. 2021; 39: 1245-1261.e6.

[44] Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 2003; 302: 1036-1038.

[45] Peña-Blanco A, García-Sáez AJ. Bax, Bak and beyond - mitochondrial performance in apoptosis. FEBS J. 2018; 285: 416-431.

[46] You H, Pellegrini M, Tsuchihara K, et al. FOXO3a-dependent regulation of puma in response to cytokine/growth factor withdrawal. J Exp Med. 2006; 203: 1657-1663.

[47] Li X, Qu Y, Yang Q, et al. Cellular localization of FOXO3 determines its role in cataractogenesis. Am J Pathol. 2023; 193: 1845-1862.

[48] Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000; 14: 121-141.

[49] Pazin MJ, Kadonaga JT. What's up and down with histone deacetylation and transcription? Cell. 1997; 89: 325-328.

[50] Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 2006; 20: 1405-1428.

[51] Hu X, Lazar MA. Transcriptional repression by nuclear hormone receptors. Trends Endocrinol Metab. 2000; 11: 6-10.

[52] Wu S, Lu J, Zhu H, et al. A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer. Cancer Lett. 2024; 581: 216508.

[53] Ye F, Dewanjee S, Li Y, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023; 22: 105.

[54] Gertz J, Savic D, Varley KE, et al. Distinct properties of cell-type-specific and shared transcription factor binding sites. Mol Cell. 2013; 52: 25-36.

RIGHTS & PERMISSIONS

2024 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.